Later-line therapy is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Peking Union Medical College Hospital. Registered phase: Not applicable. Conditions studied include Pancreatic Cancer; Resectable Carcinoma; Locally Advanced.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05802394 | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Locally Advanced |
Not applicable | Recruiting |
| NCT05802407 | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Resectable Carcinoma |
Not applicable | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Cancer | 2 |
| Resectable Carcinoma | 1 |
| Locally Advanced | 1 |
| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 2 |
| Register | Later-line therapy trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Later-line therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Later-line therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.